Bertilimumab: Phase II start

In April, Immune Pharmaceuticals will begin a double-blind, placebo-controlled, international Phase II trial to evaluate 7 mg/kg IV bertilimumab every other week for 4 weeks in about 90 patients with active moderate to severe UC. Immune Pharmaceuticals has rights to the product from iCo Therapeutics, which has rights from AstraZeneca's MedImmune LLC subsidiary under a 2007 deal. iCo Therapeutics retains rights to the product for ophthalmic indications, including ocular allergies and wet age-related macular degeneration (AMD). ...